Thus, our findings, along with other studies58,59, raise the possibility that drugs that activate or inhibit HTR7 may be useful as immunomodulatory agents for treating human enteric infections as well as for managing inflammatory bowel disease. The gene discussed is HTR7; the disease is inflammatory bowel disease.